Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

ARA-290 (Cibinetide)vsThymosin Beta-4

A peptide that awakens your body's natural repair system to heal damaged nerves and reduce pain

The body's natural healing peptide that accelerates tissue repair and reduces inflammation

Healing & RecoveryHealing & Recovery

At a Glance

Quick
comparison

Dose Range

ARA-290 (Cibinetide)

0.16 mg–0.8 mg mg

Thymosin Beta-4

2–5 mg

Frequency

ARA-290 (Cibinetide)

Once daily

Thymosin Beta-4

Twice weekly

Administration

ARA-290 (Cibinetide)

Subcutaneous injection

Thymosin Beta-4

Subcutaneous injection

Cycle Length

ARA-290 (Cibinetide)

Ongoing/indefinite

Thymosin Beta-4

8-12 weeks

Onset Speed

ARA-290 (Cibinetide)

Moderate (1-2 weeks)

Thymosin Beta-4

Moderate (1-2 weeks)

Evidence Level

ARA-290 (Cibinetide)

Moderate human trials (Phase 1-2)

Thymosin Beta-4

Moderate human trials (Phase 1-2)

Efficacy

Benefit
ratings

ARA-290 (Cibinetide)
Thymosin Beta-4

Nerve Regeneration

ARA-290 (Cibinetide)95%
Thymosin Beta-40%

Pain Management

ARA-290 (Cibinetide)85%
Thymosin Beta-40%

Tissue Protection

ARA-290 (Cibinetide)90%
Thymosin Beta-40%

Wound Healing

ARA-290 (Cibinetide)0%
Thymosin Beta-495%

Inflammation Reduction

ARA-290 (Cibinetide)0%
Thymosin Beta-488%

Tissue Regeneration

ARA-290 (Cibinetide)0%
Thymosin Beta-492%

Technical Data

Compound
specifications

ARA-290 (Cibinetide)

Molecular Formula

C51H84N16O21

Molecular Weight

1257.31 g/mol

Half-Life

Approximately 1-2 hours in circulation, but cellular effects last much longer

Bioavailability

Subcutaneous: ~100% (complete absorption); Intravenous: Immediate

CAS Number

1208243-50-8

Thymosin Beta-4

Molecular Formula

C212H350N56O78S

Molecular Weight

4963

Half-Life

Dose-dependent (increases with higher doses)

Bioavailability

100% (subcutaneous and intravenous)

CAS Number

77591-33-4

Applications

Best
suited for

ARA-290 (Cibinetide)

Treating small fiber neuropathy

ARA-290 (Cibinetide) is particularly well-suited for individuals focused on treating small fiber neuropathy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Managing neuropathic pain from diabetes or sarcoidosis

ARA-290 (Cibinetide) is particularly well-suited for individuals focused on managing neuropathic pain from diabetes or sarcoidosis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Supporting nerve regeneration after injury

ARA-290 (Cibinetide) is particularly well-suited for individuals focused on supporting nerve regeneration after injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Reducing chronic inflammation

ARA-290 (Cibinetide) is particularly well-suited for individuals focused on reducing chronic inflammation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Thymosin Beta-4

Post-Surgery Recovery

Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring

Chronic Wound Management

Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster

Tissue Regeneration

Supports repair of damaged tissues from injury, burns, or degenerative conditions

Safety Profile

Side
effects

ARA-290 (Cibinetide)

Common

  • Injection Site Reactions
  • Headache
  • Dizziness

Uncommon

  • Elevated Blood Pressure
  • Fatigue

Serious

  • Blood Clot Formation

Thymosin Beta-4

Common

  • Injection site redness
  • Injection site swelling

Uncommon

  • Temporary mild headache
  • Mild bruising at injection site
  • Transient fatigue

Serious

  • Allergic reaction

Research Status

Safety
& evidence

ARA-290 (Cibinetide)

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Not FDA approved

Safety Overview

ARA-290 is a synthetic innate repair receptor agonist that has completed Phase 2 clinical trials for small fiber neuropathy and is under active development. Animal toxicology studies show a good safety margin with no organ damage or cytotoxicity at doses far exceeding therapeutic levels. Early clinical data from Phase 2 trials demonstrate tolerability with mild injection site reactions and transient headache as primary concerns. However, immunogenicity remains a potential risk with repeated dosing of synthetic peptides, requiring anti-drug antibody monitoring. Long-term safety data beyond 12 weeks does not yet exist.

Contraindications

  • xPolycythemia vera or erythrocytosis
  • xUncontrolled hypertension
  • xPregnancy or breastfeeding
  • xKnown hypersensitivity to peptides
  • xConcurrent use with certain cancer medications

Thymosin Beta-4

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.

Contraindications

  • xActive systemic infections
  • xSevere immunosuppression
  • xHypersensitivity to thymosin or any component
  • xPregnancy (insufficient safety data)

Decision Guide

Which is
right for you?

Choose ARA-290 (Cibinetide) if...

  • Treating small fiber neuropathy
  • Managing neuropathic pain from diabetes or sarcoidosis
  • Supporting nerve regeneration after injury
  • Reducing chronic inflammation

Choose Thymosin Beta-4 if...

  • Recovering from injuries or surgery
  • Improving wound healing speed
  • Reducing inflammation
  • Minimizing scar formation